Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

5.650 -0.020 (-0.35%)
Official Closing Price Updated: 5:08 PM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aquestive Therapeutics Inc

< Previous 1 2 Next >
Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
From GlobeNewswire News Releases
Aquestive Therapeutics Receives FDA Response to Citizen’s Petition
From GlobeNewswire News Releases
Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 Guidance
From GlobeNewswire News Releases
Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting
From GlobeNewswire News Releases
Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
From GlobeNewswire News Releases
Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting
From GlobeNewswire News Releases
Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral Film
From GlobeNewswire News Releases
Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALS
From GlobeNewswire News Releases
Aquestive Therapeutics Reports Third Quarter 2019 Financial Results and Raises 2019 Guidance
From GlobeNewswire News Releases
Aquestive Therapeutics to Attend Two Upcoming Investor Conferences
From GlobeNewswire News Releases
IntelGenx Reports Second Quarter 2019 Financial Results
From GlobeNewswire News Releases
Aquestive Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
From GlobeNewswire News Releases
Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic... 
From GlobeNewswire News Releases
Aquestive Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Business Highlights on August 7, 2019
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm® technology to meet... 
From PR Newswire
Aquestive Therapeutics Completes $70 Million Debt Refinancing
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive"), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm®... 
From PR Newswire
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic... 
From PR Newswire
Aquestive Therapeutics Completes Enrollment in Libervant™ (diazepam buccal film) Crossover Study
- Files first section of rolling New Drug Application (NDA) submission with U.S. Food and Drug Administration (FDA) 
From PR Newswire
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic... 
From PR Newswire
Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
- U.S. launch of Sympazan® (clobazam) Oral Film progressing to plan 
From PR Newswire
IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics, Inc.... 
From GlobeNewswire News Releases
Aquestive Therapeutics Announces Daniel Barber Named to Chief Operating Officer
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced the... 
From PR Newswire
Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it... 
From PR Newswire
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the... 
From PR Newswire
Market Trends Toward New Normal in Smartsheet, Spok, TPG RE Finance Trust, DSP Group, Adaptimmune Therapeutics, and Aquestive Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Smartsheet Inc. (NYSE:SMAR),... 
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that... 
From PR Newswire
Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
- Secured U.S. Food and Drug Administration (FDA) approval and launched the first proprietary commercial product in its epilepsy franchise, SYMPAZAN™ (clobazam) Oral Film 
From PR Newswire
Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that... 
From PR Newswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.